Mindray (300760) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
23 Jul, 2025Executive summary
2024FY revenue reached 36.7 billion RMB, up 5.1% year-over-year, with net profit attributable to shareholders at 11.7 billion RMB, up 0.7%.
Net operating cash flow for 2024FY was 12.4 billion RMB, a 12.4% increase year-over-year.
2025Q1 saw revenue of 8.2 billion RMB, down 12.1% year-over-year, and net profit attributable to shareholders of 2.6 billion RMB, down 16.8%.
Financial highlights
Gross margin for 2024FY was 63.1%, down 1.07 percentage points year-over-year.
Net margin for 2024FY was 31.77%, down 1.38 percentage points year-over-year.
Total assets at 2024 year-end were 56.6 billion RMB, up 18.2% year-over-year; shareholders' equity rose 22.2% to 40.8 billion RMB.
Dividend payout ratio for 2024FY reached 65.1%, with total cash dividends of 7.6 billion RMB, up 8.1% year-over-year.
Outlook and guidance
Revenue in 2025 is expected to follow a typical pattern of a lower first half and higher second half, with a major turning point in year-over-year growth anticipated from Q3.
Latest events from Mindray
- Q3 revenue rebounded with international growth, but YTD net profit declined sharply.300760
Q3 202530 Oct 2025 - H1 2025 revenue and profit declined sharply, but international growth and digital transformation continue.300760
H1 202528 Aug 2025 - Double-digit profit and revenue growth, strong IVD, cardiovascular entry, high dividend.300760
H1 202423 Jul 2025 - Revenue and profit rose 8% year-over-year, led by strong international growth.300760
Q3 202423 Jul 2025 - AI-powered, multi-disciplinary solutions drive efficiency and global expansion in healthcare.300760
43rd Annual J.P. Morgan Healthcare Conference Presentation23 Jul 2025 - International growth and strong dividends offset domestic softness; recovery expected.300760
Q1 202523 Jul 2025